Posted: January 14, 2008

eFoodSafety to Enter Bio- and Nano-Technologies Industry

(Nanowerk News), Inc. (OTCBB: EFSF, has entered the bio- and nano-technologies industry and has initiated research on nano-particle ingredients that may be incorporated in whole foods, nutraceutical products and cosmeceuticals.
Nanotechnology can help enhance the delivery and efficiency of drugs throughout the body. The science of using extremely small, self-contained particles to accomplish specific tasks, nano-technology allows the body to absorb minute particles of nutrients much more efficiently than it can with nutrients at their normal sizes. At the medicinal level, the particle size is generally structured at approximately one hundred nanometers. The Freedonia Group, a leading international industrial market research company, recently projected worldwide demand for nano-materials to reach $4.2 billion by 2011 and $100 billion by 2025, with widespread use in drug delivery applications as a significant growth factor.
“This development marks a major milestone for the company as we enter the highly advanced drug delivery technology field,” says Patricia Gruden, CEO of eFoodSafety. “In particular, these technologies have the ability to help enhance our presence in the area of preventative treatments. According to the World Health Organization, up to 80% of heart disease, stroke, and diabetes, and 40% of cancer could be prevented. We believe bio and nano-technologies can help improve drug delivery statistics by reducing negative effects on non-affected areas of the body.”
eFoodSafety now has a highly synergistic product portfolio and cohesive group of subsidiaries and industry alliances in the food, medical, and nutritional categories that create compelling opportunities for both research and development and distribution of biotech innovations aimed at improving health at the personal and institutional levels.
According to PricewaterhouseCoopers, the global pharmaceutical market will more than double in value to $1.3 trillion by 2020. Much of this surge will be fueled by the demand for new medicines, including those for prevention, as the worldwide population suffers more and more health problems including obesity, diabetes, cardiovascular disease, cancer, and exposure to antibiotic resistant pathogens. One of the major concerns is that while the typical life span continues to increase, there will not be a concurrent increase in the quality of life. These factors create a virtually limitless market for biotech health products. In the U.S. alone, there are over 1,000 companies working in the biotechnology industry with combined annual revenue of over $50 billion.
About, Inc., based in Scottsdale, Arizona, is dedicated to improving health conditions around the world through its innovative technologies. The company’s Knock-Out Technologies, Ltd. subsidiary has developed an environmentally safe sporicidal product formulated entirely of food-grade components that eradicates anthrax and a germicidal product, Citroxin™ (formerly named Big Six Plus) – EPA Reg. No. 82723-1 that kills six major bacteria: E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, and Streptococcus, Avian Influenza, and Black Mold. The sporicidal product has completed its final efficacy laboratory study requisite for EPA registration. In the study, it eradicated both Clostridium Sporogenes and Bacillus Subtilis with 100% efficacy on both hard and porous surfaces. The OraPhyte™ product, which has been tested and shown to be effective at eradicating nematodes by the U.S. Department of Agriculture, is currently at three major universities with outstanding Agricultural Departments undergoing crop-specific research.
The company’s Cinnergen™ is a clinically-studied, non-prescription liquid whole food nutritional supplement that promotes healthy glucose metabolism, is available for sale at ( and through national retailers; its Cinnechol™ is a multi-faceted nutritional supplement specifically designed to naturally reduce total cholesterol levels without causing any side effects. The company has entered into a joint venture agreement with CK41 Direct, Inc. to launch the PurEffect™ anti-acne skin care system.
The company’s iBoost, Inc. subsidiary is the distributor of the Immune Boost Bar™, a non-dairy, no refined sugar, all-natural and comprehensive multi-nutrient product that helps fortify the body’s immune system. The product contains Citroxin™, eFoodSafety’s proprietary all natural supplement proven effective in fighting several types of harmful bacteria, and forty active compounds that assist with enhancing immunity, detoxification, cleansing, and metabolic efficiency. The Immune Boost Bar™ is available in three delicious flavors: chocolate, oatmeal-raisin, mint and peanut butter and can be purchased at
The company’s MedElite, Inc. subsidiary distributes clinically proven products to physicians who then prescribe the products for their patients. It is the owner of the Talsyn™-CI/bid Scar Cream, a product that has been clinically proven to facilitate and improve the appearance, redness and strength of scars (, as well as seven (7) other products in the Talsyn™ line.
Please visit the company’s website at:
Safe Harbor Forward-Looking Statements
Statements contained in this release that are not strictly historical are “forward-looking statements.” Such forward-looking statements are sometimes identified by words such as “intends,” “anticipates,” “believes,” “expects” and “hopes.” The forward-looking statements are made based on information available as of the date hereof, and the Company assumes no obligation to update such forward-looking statements. Editors and investors are cautioned that such forward-looking statements involve risks and uncertainties that could cause the Company’s actual results to differ materially from those in these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the Company’s products and services, our ability to continue to develop markets, general economic conditions, our ability to secure additional financing for the Company and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.
Subscribe to a free copy of one of our daily
Nanowerk Newsletter Email Digests
with a compilation of all of the day's news.
These articles might interest you as well: